Persistent Asset Partners Ltd Makes New $1.59 Million Investment in United Therapeutics Corporation $UTHR

Persistent Asset Partners Ltd acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, Holdings Channel reports. The firm acquired 3,267 shares of the biotechnology company’s stock, valued at approximately $1,592,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Darwin Global Management Ltd. purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $317,617,000. Norges Bank purchased a new stake in United Therapeutics during the 4th quarter worth approximately $293,418,000. Dimensional Fund Advisors LP increased its holdings in United Therapeutics by 3.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 528,210 shares of the biotechnology company’s stock worth $257,405,000 after purchasing an additional 15,394 shares during the last quarter. Baillie Gifford & Co. purchased a new stake in United Therapeutics during the 4th quarter worth approximately $157,390,000. Finally, Victory Capital Management Inc. increased its holdings in United Therapeutics by 108.1% during the 4th quarter. Victory Capital Management Inc. now owns 228,383 shares of the biotechnology company’s stock worth $111,280,000 after purchasing an additional 118,628 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,598,874. The trade was a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 644,468 shares of company stock worth $363,647,822. Insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the topic of several analyst reports. Bank of America lifted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Trading Down 0.2%

Shares of UTHR opened at $548.27 on Wednesday. The firm has a market cap of $23.27 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.79 and a beta of 0.57. The stock has a 50 day moving average of $566.12 and a 200-day moving average of $522.52. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.63 EPS. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.